Citations

Clear

16280 citation(s) found for "Yu, David".

OT3-01-14: N0937: Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.
Moreno‐Aspitia, Alvaro , Rowland, K. M., Liu, Hanxue, Hillman, DW, Stella, PJ, Perez, EA, Hillman, David W.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 24_Supplement | Pages: OT3-01-14-OT3-01-14

10.1158/0008-5472.sabcs11-ot3-01-14 Get It

Abstract Background Tumors that are negative for estrogen and progesterone receptors and do not over express HER2 are referred as “triple negative” breast cancer (TNBC). These tumors are characterized by unique molecular profiles on gene expression arrays, aggressive behavior with a high recurrence rate, an increased risk of visceral metastases, poor prognosis and lack of targeted therapies. Brostallicin is a novel synthetic compound from the class of DNA minor groove binding (MGB) anti-cancer agents. It retains activity in cancer cells resistant to alkylating agents, topoisomerase I inhibitors and is fully active against DNA-mismatch repair deficient tumor cells. Cells expressing relatively high glutathione/glutathione S-transferase (GSH/GST) levels are more susceptible to brostallicin antitumor efficacy. Cisplatin administration increases expression of GST in tumor cells leading to an increased anti-tumor efficacy of brostallicin. Trial design: Single-stage phase II study — based on the effects of cisplatin on GSH/GST levels in preclinical models, the most reasonable sequence to explore was cisplatin on Day 1 followed by brostallicin on Day 2 repeated every 21 days. Eligibility criteria: Women or men ≥18 years of age with confirmed adenocarcinoma of the breast with clinical evidence of measurable metastatic disease and triple negative subtype according to current ASCO CAP guidelines [ER/PR ≤1%; HER2 negative), who received 0–4 prior chemotherapy regimens in the metastatic setting; with adequate hematologic, renal and hepatic functions; and no active CNS metastases. Aims: To study the efficacy of the novel drug, brostallicin, as well as to serve as proof of concept of its mechanism of action in TNBC. The primary endpoint is to evaluate clinical efficacy of the combination of brostallicin and cisplatin in the treatment of patients with metastatic TNBC, as measured by progression-free survival (PFS) at 3 months with 89% power (0.10 significance level) to detect an absolute difference of 20%. Secondary endpoints include ORR by RECIST, duration of response, 6-month PFS, overall survival (OS) and adverse event profile. Tertiary endpoints include assessment of 1) GSH levels prior to the administration of cisplatin and of brostallicin; and 2) the prevalence of BCRA-1 mutation by IHC in the primary or metastatic tumor. Statistical methods: The largest 3-month PFS proportion where the proposed treatment regimen would be considered ineffective in this population was estimated at 35% based on the median PFS of 60 days in patients with metastatic TNBC enrolled in the N0234 trial (erlotinib and gemcitabine as 1st/2nd line), and the smallest 3-month PFS success proportion that may warrant subsequent studies with the proposed regimen in this patient population was estimated at 55%. The interim analysis will be reported when the 20th eligible patient has been followed for 3 months. Present accrual and target accrual: 21 patients have been accrued at the time of abstract submission (June 2011). Target accrual is 42 evaluable patients. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-14.
Abstract B176: Synergistic induction of apoptosis by the histone-deacetylase inhibitor, Panobinostat, combined with ABT-737 or rhTRAIL, in multiple myeloma
Matthews, Geoffrey M. , Banks, Kellie M., Stanley, Kym L., Faulkner, David, Bergsagel, Leif, Chesi, Marta , Atadja, Peter, Shortt, Jake , Johnstone, Ricky W.

Mayo Clinic

Molecular Cancer Therapeutics | June 27, 2012 | Volume: 8 | Issue: 12_Supplement | Pages: B176-B176

10.1158/1535-7163.targ-09-b176 Get It

Abstract Introduction:The histone deacetylase inhibitor (HDACi) Panobinostat (LBH-589, Novartis Pharmaceutical Corp) belongs to a new class of chemotherapeutics with demonstrated anticancer activities in laboratory studies and within the clinic. Using pre-clinical models of leukemia and lymphoma we have demonstrated that HDACi mediate their therapeutic effects via the intrinsic apoptosis pathway. Here we investigated the ability of Panobinostat to induce apoptosis in human multiple myeloma (MM) cell lines, alone and in combination with agents that target pro-survival Bcl-2 proteins (ABT-737) and the extrinsic apoptosis pathway (rhTRAIL). Moreover, we have used the Vk*myc murine model of MM to demonstrate the therapeutic efficacy of Panobinostat and its ability to induce apoptosis in MM cells in vivo. Methods: JJN3, OPM-2, RPMI-8226 and U266 MM cell lines were incubated with Panobinostat, ABT-737 or rhTRAIL alone or in combination. Cell viability and cell cycle were assessed using flow cytometry. Histone acetylation was assessed by western blot. C57BL/6 mice (n = 32) bearing transplanted Vk*myc MM (2 months post-transplant) were treated with Panobinostat (25mg/kg, 4 days; 15mg/kg 5 days/week, 3 weeks) or vehicle (D5W). Serum paraprotein levels were assessed weekly in all mice. Mice were sacrificed at various time points to measure apoptotic and therapeutic effects. Results: Treatment of MM cell lines with Panobinostat resulted in time- and dose-dependent induction of apoptosis associated with G1 phase arrest and histone H3/H4 acetylation. Combinations of Panobinostat with ABT-737 or rhTRAIL synergised to mediate robust and rapid apoptosis in the human MM cells. Serum paraprotein in mice bearing Vk*myc MM cells was significantly reduced after 4 days of high dose (25mg/ml) Panobinostat compared with vehicle treated mice (p<0.01) and remained at this reduced level for the treatment period (≤60% reduction compared with vehicle treated mice). This was associated with a significant induction of apoptosis and a reduction in CD-138+ plasma cells within the bone marrow. Removal of treatment was associated with increased paraprotein levels, progression of extramedullary disease and death endpoints. Overall, Panobinostat induced a significant survival advantage compared with vehicle (median=36.5 vs. 16 days, p<0.01). Conclusions: These results suggest that the HDACi Panobinostat has single agent activity against MM cell lines in vitro and provides a significant therapeutic benefit to mice bearing syngeneic MM tumors. Moreover, combination therapies consisting of HDAC inhibitors with agents that target pro-survival Bcl-2 proteins or the TRAIL apoptosis pathway may provide a rational approach to the treatment of MM. Future studies will investigate the molecular events underpinning the effects mediated by Panobinostat, ABT-737 and TRAIL in the Vk*myc MM model. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B176.
Abstract CN06-03: Randomized double-blinded phase II trial of esomeprazole versus esomeprazole + two doses of aspirin in Barrett's esophagus patients
Sontag, Steven, Cruz-Correa, Marica, Weinberg, David S. , Chak, Amitabh , Fleischer, David, Smyrk, Thomas C. , Butar, Navtej, Foster, Nathan R. , Romero, Yvonne , Corley, Douglas A. , DeVault, Kenneth R. , Marcon, Norman E. , Schnell, Thomas , Falk, Gary W. , Hur, Chin

Mayo Clinic

Cancer Prevention Research | June 27, 2012 | Volume: 4 | Issue: 10_Supplement | Pages: CN06-03-CN06-03

10.1158/1940-6207.prev-11-cn06-03 Get It

Abstract Background and Aims: In patients with Barrett's esophagus (BE), reflux-induced injury promotes esophageal adenocarcinoma, presumably through cyclooxygenase 2 (COX-2) related pathways. Proton pump inhibitors (PPIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) may interrupt reflux-associated carcinogenesis by reducing acid exposure and subsequent inflammation. However, clinical trial data regarding the chemopreventive efficacy of a PPI + NSAID combination are limited. The aim of this multi-center, randomized, phase II trial was to assess the effects of a 28-day intervention with esomeprazole 40 mg bid and aspirin 81 mg qd, 325 mg qd, or placebo qd on tissue prostaglandin E2 (PGE2) concentrations in BE patients. Methods: Using the infrastructure of the Cancer Prevention Network, participants (> 18 years) with histologically confirmed non dysplastic BE were randomly assigned to receive one of three interventions for 28 days: (arm A) esomeprazole 40 mg bid+ aspirin 81 mg placebo qd + aspirin 325 mg placebo qd (n=42); (arm B) esomeprazole 40 mg bid+ aspirin 81 mg qd + aspirin placebo 325 qd (n=63); (arm C) esomeprazole 40 mg bid + aspirin 81 mg qd placebo + aspirin 325 mg qd (n=63). Esophageal biopsies were obtained pre- and post-intervention to assess change in PGE2 concentration as the primary endpoint. Results: In total, 122 participants were randomized, 121 (99%) completed the trial per protocol, and 115 (94%) were evaluated for the primary endpoint. Baseline characteristics were similar across intervention arms. The absolute change (mean + SD) in tissue PGE2 concentration was −67.6 (229.68) in Arm A, −120.9 (281.28) in Arm B (p = 0.10 vs Arm A) and −174.9 (263.62) in Arm C (p = 0.02 vs Arm A). Conclusions: In combination with esomeprazole 40 mg twice per day, aspirin 325 mg per day significantly reduced tissue PGE2 concentration in BE patients after a 28-day intervention, as compared to aspirin placebo. Given the relevance of PGE2 pathways in BE-associated carcinogenesis, further evaluation of this chemoprevention strategy in larger, more definitive phase III trials is warranted. Citation Information: Cancer Prev Res 2011;4(10 Suppl):CN06-03.
Abstract A22: Sensitive detection of mutant KRAS in colorectal tissue using the multiplex QuARTS™ assay
Oldham-Haltom, Rebecca, Hunt, O. J., Domanico, Mike, Taylor, William, Ahlquist, David A. , Lidgard, Graham P. , Leduc, Christine M.

Mayo Clinic

Cancer Prevention Research | June 27, 2012 | Volume: 4 | Issue: 10_Supplement | Pages: A22-A22

10.1158/1940-6207.prev-11-a22 Get It

Abstract Background: Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States, yet it is potentially the most treatable and preventable cancer with effective screening. Exact Sciences has developed a multi-biomarker CRC screening test that targets DNA methylation, DNA mutations, and hemoglobin in stool. The aim of this study was to evaluate the analytical accuracy of a novel assay for the detection of KRAS mutation sequences at Codons 12 and 13 in well-characterized colorectal tissues. Methodology: A multiplexed KRAS assay was designed utilizing QuARTS (Quantitative Allele-specific Real-time Target and Signal amplification), a highly sensitive technology that combines allele-specific DNA amplification with invasive cleavage chemistry to generate signal during each amplification cycle similar to real-time PCR. The assay, which detects seven KRAS mutations and the reference gene β-actin, was used to assess 87 colorectal tissue samples (52 CRCs, 16 adenomas ≥ 1cm, and 19 normal epithelia) as determined by Mayo Clinic Pathology. Samples were obtained by microdissection of fresh frozen tissue biopsies. DNA was extracted by Mayo Clinic using a standardized chloroform/phenol methodology. The genotypes of each sample were established using dye terminator dideoxy sequencing in both the forward and reverse orientations. Copy numbers of KRAS mutations and β-actin were determined by conventional comparison against standard curves. KRAS data are reported as percent mutation and calculated by dividing mutant copies by β-actin copies and multiplying by 100. Results: Based on sequencing data: the 52 CRC samples contained 22 KRAS mutations and 30 wild-type genotypes, the 16 adenomas ≥ 1cm contained 8 mutations and 8 wild-type genotypes, and the 19 normal tissues contained all wild-type genotypes. The QuARTS assay detected 100% of the KRAS mutations in the CRC and adenomas and provided excellent differentiation between wild-type and mutation, with the highest percent KRAS mutation of normal wild-type samples at 0.55% and the lowest percent mutation of KRAS positive samples at 8.34%. Based on this data, this assay has the potential to be more sensitive analytically than standard sequencing. Conclusion: The QuARTS assay detects KRAS mutations in tissue with high sensitivity and specificity. This assay method could provide an accurate and high throughput approach to detection of KRAS mutations in biospecimens for multiple clinical applications. Citation Information: Cancer Prev Res 2011;4(10 Suppl):A22.
Is HOT a Cool Treatment for Type 1 Diabetes?
Rajagopalan, Govindarajan , Kudva, Yogish C. , David, Chella S.

Mayo Clinic

Diabetes | June 22, 2012 | Volume: 61 | Issue: 7 | Pages: 1664-1666

10.2337/db12-0527 | PMID 22723274 Get It

Neural Networks, Cognition, and Diabetes: What Is the Connection?
Jones, David T.

Mayo Clinic

Diabetes | June 22, 2012 | Volume: 61 | Issue: 7 | Pages: 1653-1655

10.2337/db12-0402 | PMID 22723270 Get It

Everolimus‐eluting stents and zotarolimus‐eluting stents for percutaneous coronary interventions
Ye, Zhong, Wu, Chuntao , Walford, Gary, Holmes, David R. , Jacobs, Alice K. , Stamato, Nicholas J., Venditti, Ferdinand J. , Sharma, Samin, Fergus, Icilma, King, Spencer B., Hannan, Edward L. , Sharma, Samin

Mayo Clinic

Catheterization and Cardiovascular Interventions | June 18, 2012 | Volume: 81 | Issue: 7 | Pages: 1097-1105

10.1002/ccd.24512 | PMID 22707353 Get It

ObjectivesTo compare 2‐year outcomes (mortality, mortality/myocardial infarction (MI), target vessel PCI (TVPCI), and target lesion PCI (TLPCI)) for patients receiving EES and ZES.BackgroundThe utilization of drug‐eluting coronary stents (DES) among patients undergoing percutaneous coronary interventions (PCI) has increased dramatically in the last decade. Everolimus‐eluting stents (EES) and ENDEAVOR zotarolimus eluting stents (ZES) constitute the latest generation of approved DES in the United States, but little is known about their relative effectiveness.MethodsNew York patients undergoing EES and ZES revascularization without any other type of stent between 7/08 and 12/08 were propensity matched at the hospital level using multiple patient, operator, and hospital characteristics, and matched patients were followed through the end of 2010 to obtain comparative 2‐year outcomes.ResultsA total of 3286 patients were propensity‐matched. Patients receiving EES had a significantly lower TVPCI rate (9.0% vs. 11.9%, AHR = 1.31, 95% CI (1.04, 1.65)) and a significantly lower TLPCI rate (6.0% vs. 8.3%, AHR = 1.35, 95% CI (1.02, 1.79)). There was no significant difference between EES and ZES for mortality or MI/mortality.ConclusionsThere were no significant differences in the hard endpoints of death or MI between patients who received EES versus those who received ZES (ENDEAVOR). Patients with EES experienced lower repeat revascularization rates than patients with ZES at 24 months. © 2012 Wiley Periodicals, Inc.
Calcinosis cutis in autoimmune connective tissue diseases
Gutierrez, Albert, Wetter, David A.

Mayo Clinic

Dermatologic Therapy | June 14, 2012 | Volume: 25 | Issue: 2 | Pages: 195-206

10.1111/j.1529-8019.2012.01492.x | PMID 22741938 Get It

Dental Abnormalities in Schimke Immuno-osseous Dysplasia
Morimoto, Marie , Kérourédan, Olivia , Gendronneau, M., Shuen, Chao S, Baradaran‐Heravi, Alireza , Asakura, Yumi , Basiratnia, Mitra , Bogdanović, Radovan, Bonneau, Dominique , Buck, A., Charrow, Joel , Cochat, Pierre , DeHaai, Kristi A. , Fenkçi, M Semin, Frange, Pierre, Fründ, Stefan, Fryssira, Helen , Keller, Kory, Kirmani, Salman , Kobelka, Christine, Lewis, David B. , Massella, Laura , McLeod, D. Ross, Milford, David V. , Nobili, François, Olney, Ann Haskins, Semerci, C. Nur, Stajic, Nastasa, Stein, Anja , Taque, Sophie, Zonana, J., Lücke, Thomas , Hendson, Glenda, Bonnaure‐Mallet, Martine , Frange, Pierre , Köhler, Katharina , Boerkoel, Cornelius F.

Mayo Clinic

Journal of Dental Research | June 14, 2012 | Volume: 91 | Issue: 7_suppl | Pages: S29-S37

10.1177/0022034512450299 | PMID 22699664 Get It

Described for the first time in 1971, Schimke immuno-osseous dysplasia (SIOD) is an autosomal-recessive multisystem disorder that is caused by bi-allelic mutations of SMARCAL1, which encodes a DNA annealing helicase. To define better the dental anomalies of SIOD, we reviewed the records from SIOD patients with identified bi-allelic SMARCAL1 mutations, and we found that 66.0% had microdontia, hypodontia, or malformed deciduous and permanent molars. Immunohistochemical analyses showed expression of SMARCAL1 in all developing teeth, raising the possibility that the malformations are cell-autonomous consequences of SMARCAL1 deficiency. We also found that stimulation of cultured skin fibroblasts from SIOD patients with the tooth morphogens WNT3A, BMP4, and TGFβ1 identified altered transcriptional responses, raising the hypothesis that the dental malformations arise in part from altered responses to developmental morphogens. To the best of our knowledge, this is the first systematic study of the dental anomalies associated with SIOD.
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
Adair, Robert A. , Roulstone, Victoria , Scott, Karen J. , Morgan, Ruth, Nuovo, Gerard J., Fuller, Martin, Beirne, Deborah , Jennings, Victoria A. , Rose, Ailsa , Fraser, Sheila , Dave, Rajiv , Anthoney, David Alan, Merrick, Alison, Prestwich, Robin, Aldouri, Amer, Donnelly, Oliver , Pandha, Hardev , Selby, Peter J. , Vile, Richard G. , Toogood, Giles J. , Harrington, Kevin J. , Melcher, Alan , West, Emma J. , Kyula, Joan , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin , Dave, Rajiv V

Mayo Clinic

Science Translational Medicine | June 13, 2012 | Volume: 4 | Issue: 138 | Pages: No page available

10.1126/scitranslmed.3003578 | PMID 22700953 Get It

Oncolytic reovirus is carried by cells to tumors and protected from neutralizing antibodies in the circulation.